Therapeutic potential of a peptide targeting BCL-2 cell guardians in cancer

Journal of Clinical Investigation

Volumn 122, Issue 6, 2012, Pages 1965-1967

  Adams, Jerry M ^a,b  

^a WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; ABT 199; ANTINEOPLASTIC AGENT; BH3 PROTEIN; BIM PROTEIN; BIM STABILIZED ALPHA HELIX OF BCL 2 DOMAIN; NAVITOCLAX; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN MCL 1; UNCLASSIFIED DRUG;

APOPTOSIS; BLOOD DISEASE; CANCER THERAPY; CHRONIC LYMPHATIC LEUKEMIA; DRUG MEGADOSE; HEMATOLOGY; HUMAN; LEUKEMIA; NONHUMAN; NOTE; PRIORITY JOURNAL; PROTEIN TARGETING; TUMOR CELL; XENOGRAFT;

ANIMALS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; HUMANS; LEUKEMIA, MYELOID, ACUTE; MEMBRANE PROTEINS; PEPTIDES; PROTO-ONCOGENE PROTEINS;

EID: 84861815473     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI64120     Document Type: Note

References (14)

1. Strasser A, Cory S, Adams JM. Deciphering the rules of programmed cell death to improve therapy of cancer and other diseases. EMBO J. 2011;30(18):3667-3683.
2. Lessene G, Czabotar PE, Colman PM. BCL-2 family antagonists for cancer therapy. Nat Rev Drug Discov. 2008;7(12):989-1000.
3. Oltersdorf T, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature. 2005;435(7042):677-681. (Pubitemid 40825512)
4. Tse C, et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 2008;68(9):3421-3428.
5. van Delft MF, et al. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell. 2006;10(5):389-399. (Pubitemid 44711953)
6. Roberts AW, et al. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol. 2012;30(5):488-496.
7. Mason KD, et al. Programmed anuclear cell death delimits platelet life span. Cell. 2007;128(6):1173-1186. (Pubitemid 46427871)
8. LaBelle JL, et al. A stapled BIM peptide overcomes apoptotic resistance in hematologic cancers. J Clin Invest. 2012;122(6):2018-2031.
9. Walensky LD, et al. Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix. Science. 2004;305(5689):1466-1470. (Pubitemid 39167667)
10. Gavathiotis E, et al. BAX activation is initiated at a novel interaction site. Nature. 2008;455(7216):1076-1081.
11. Gavathiotis E, Reyna DE, Davis ML, Bird GH, Walensky LD. BH3-triggered structural reorganization drives the activation of proapoptotic BAX. Mol Cell. 2010;40(3):481-492.
12. Chen L, et al. Differential targeting of pro-survival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell. 2005;17(3):393-403. (Pubitemid 40193310)
13. Certo M, et al. Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell. 2006;9(5):351-365. (Pubitemid 43668734)
14. Bouillet P, et al. Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity. Science. 1999;286(5445):1735-1738. (Pubitemid 129515880)